HIGHLIGHTS
- who: Beate Bittner from the A SC formulation for natalizumab is approved in MS in the EU have published the paper: Customer-centric product presentations for monoclonal antibodies, in the Journal: (JOURNAL)
- what: The first approach aims at precise delivery of biotherapeutics to gastrointestinal tissue thus avoiding high systemic exposure and potentially associated side effects. Assuming the scientific concept is confirmed in larger clinical trials and treatment can be realized at commercializable dose levels and dosing regimens, this approach has the potential to provide new clinical strategies in the future (Zhang et_al 2021).
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.